Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist DiagnosisRecruiting
NCT07245576N/AUpdated May 27, 2026
Sponsor: AstraZeneca
Asthma · COPD
Argentina, Egypt, Mexico, Saudi Arabia, Taiwan +2 more
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)Recruiting
NCT03848052N/AUpdated May 27, 2026
Sponsor: UNICANCER
Lung Cancer
France
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)Active Not Recruiting
NCT03875235Phase 3Updated May 26, 2026
Sponsor: AstraZeneca
Biliary Tract Neoplasms
United States, Argentina, Bulgaria, Chile, China +12 more
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical PracticeActive Not Recruiting
NCT05637112N/AUpdated May 26, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
Austria, Belgium, Canada, France, Germany +4 more
VITALIZE.Use and Effectiveness of Sodium Zirconium Cyclosilicate (LokelmaTM) in the Real-world Setting in SpainCompleted
NCT06635499N/AUpdated May 22, 2026
Sponsor: AstraZeneca
Hyperkalaemia
Spain
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerRecruiting
NCT06954480Phase 2Updated May 22, 2026
Sponsor: Queen Mary University of London
Triple Negative Breast Cancer
United Kingdom
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive Not Recruiting
NCT05043090Phase 3Updated May 22, 2026
Sponsor: AstraZeneca
Papillary Renal Cell Carcinoma
United States, Argentina, Australia, Brazil, Canada +20 more
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck CancerCompleted
NCT02308072Phase 1Updated May 22, 2026
Sponsor: University College, London
Head and Neck Cancer
United Kingdom
The CATALINA StudyRecruiting
NCT05008081N/AUpdated May 22, 2026
Sponsor: Wim Janssens
Chronic Obstructive Pulmonary Disease Exacerbation
Austria, Belgium, France, Germany, Italy +6 more
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)Completed
NCT04931563Phase 3Updated May 20, 2026
Sponsor: AstraZeneca
Active Systemic Lupus Erythematosus
China, Hong Kong, Philippines, South Korea, Taiwan +1 more
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKDEnrolling By Invitation
NCT05374291Phase 3Updated May 20, 2026
Sponsor: University Medical Center Groningen
Kidney Disease, Chronic · Renal Transplant Failure · Heart Failure · Kidney Failure
Australia, Belgium, Germany, Netherlands, Singapore +1 more
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive Not Recruiting
NCT05057494Phase 3Updated May 19, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
United States, Australia, Czechia, France, Hungary +2 more
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor CancerActive Not Recruiting
NCT05678010Phase 1Updated May 18, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Solid Tumor · Metastatic Solid Tumor · Solid Carcinoma · Solid Tumor, Adult
United States
HER2-positive Metastatic Breast Cancer in KazakhstanNot Yet Recruiting
NCT07593196N/AUpdated May 18, 2026
Sponsor: AstraZeneca
Metastatic Breast Cancer
Kazakhstan
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruiting
NCT04941716Phase 2Updated May 18, 2026
Sponsor: Fred Hutchinson Cancer Center
Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia · Refractory Small Lymphocytic Lymphoma
United States
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.Recruiting
NCT07222917Phase 2Updated May 18, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease and Hypertension
United States, Argentina, Bulgaria, Canada, South Korea +6 more
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Active Not Recruiting
NCT05374512Phase 3Updated May 15, 2026
Sponsor: AstraZeneca
Breast Cancer
United States, Argentina, Belgium, Brazil, Canada +18 more
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Active Not Recruiting
NCT04622319Phase 3Updated May 15, 2026
Sponsor: Daiichi Sankyo
HER2-Positive Primary Breast Cancer · Residual Invasive Breast Cancer
United States, Argentina, Australia, Belgium, Brazil +26 more
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular FeaturesRecruiting
NCT05255653Phase 2, Phase 3Updated May 15, 2026
Sponsor: Leiden University Medical Center
Endometrial Cancer
Canada, France, Netherlands, United Kingdom
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active Not Recruiting
NCT06606847Phase 2Updated May 15, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
Russia
Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)Not Yet Recruiting
NCT06734884Phase 2Updated May 15, 2026
Sponsor: University Hospital, Lille
DRESS Syndrome
France
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyCompleted
NCT05665374N/AUpdated May 15, 2026
Sponsor: AstraZeneca
Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
Japan
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.Recruiting
NCT06995820Phase 1Updated May 15, 2026
Sponsor: AstraZeneca
Healthy
United States
A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiAActive Not Recruiting
NCT05939128N/AUpdated May 15, 2026
Sponsor: AstraZeneca
Breast Cancer
Russia
Barriers and Facilitators of Persistence With Adjuvant OsimertinibNot Yet Recruiting
NCT07542210N/AUpdated May 14, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
China

Previous page Next page